Answers are grounded in this paper and cite their sources.
immunoglobulin-like transcript 7 receptor, complement component fragment 5a receptor and viral attachment to the human cell were under investigation for management of severely ill patients with COVID-19. Among these, about 65 clinical trials are targeting IL-6 inhibition as the most promising one and Tocilizumab, an IL-6 inhibitor is considered to be the potential candidate to treat cytokine storm associated with the COVID-19.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: